Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 4/2004

01-11-2004 | Original paper

Approval times and the safety of new pharmaceuticals

Author: Niklas Rudholm

Published in: The European Journal of Health Economics | Issue 4/2004

Login to get access

Abstract

This study examined the relationship between the approval times for new pharmaceuticals and the number of adverse drug reactions reported to the Swedish Medical Products Agency. Yearly time-series data concerning the number of adverse drug reactions, as well as data concerning prices and quantities sold for 25 pharmaceutical substances during the period 1972–1996 were used. The results show that shorter approval times are associated with more adverse drug reactions, but also that the effects are quite small.
Appendix
Available only for authorised users
Literature
1.
Andersson F, Hertzman P (1993) Effective patent life of drugs in Sweden—a comparison with international studies. Manage Decis Econ 14:53–63
2.
Bakke OM, Manocchia M, Deabajo F, Kaitin KI, Lasagna L (1995) Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993—a regulatory perspective. Clin Pharmacol Ther 58:108–117PubMed
3.
Cameron AC, Trivedi PK (1998) Regression analysis of count data. Cambridge University Press: Cambridge
4.
Hausman JA, Hall BH, Griliches Z (1984) Econometric models for count data with an application to the patents—R and D relationship. Econometrica 52:909–938
5.
Olson MK (1995) Regulatory agency discretion among competing industries: inside the FDA. J Law Econ Organ 11:379–405
6.
Olson MK (2002) Pharmaceutical policy change and the safety of new drugs. J Law Econ 45:615–642CrossRef
7.
Pieterson EA (1992) A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States. J Clin Pharmacol 32:889–896PubMed
8.
Rawson NSB, Kaitin KI (2003) Canadian and US drug approval times and safety considerations. Ann Pharmacother 37:1403–1408CrossRefPubMed
9.
Shulman SR, Kaitin KI (1996) The prescription drug user fee act of 1992: a 5-year experiment for the industry and the FDA. Pharmacoeconomics 9:121–133PubMed
10.
Thomas KE, McAuslane N, Parkinson C, Walker SR, Luscombe DK (1998) A study of trends in pharmaceutical regulatory approval times for nine major markets in the 1990s. Drug Inform J 32:787–801
Metadata
Title
Approval times and the safety of new pharmaceuticals
Author
Niklas Rudholm
Publication date
01-11-2004
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 4/2004
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-004-0247-0

Other articles of this Issue 4/2004

The European Journal of Health Economics 4/2004 Go to the issue

Original paper

What reimbursement for coronary revascularization with drug-eluting stents?

Congress Papers

Data envelopment analysis based bonus payments

Pricing and reimbursement

Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden

Original papers

Exponential health utility

Original Paper

Willingness to pay for dental fear treatment

Original Papers

Re-scaling social preference data: implications for modelling